Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Is AOD-9604 approved by the FDA
You may not copy, modify, distribute, display, transmit, perform, publish or sell any of the copyrightable material on this website
The authors identified future areas of investigation including male models, long-term treatment effects, and combination with other NAD+ precursors such as NMN
What the Research Says About Safety Clinical studies on AOD9604 indicate that the peptide is generally welltolerated: In human trials, no significant adverse effects were reported at doses up to 1 mg/day (safety summary) Unlike growth hormone therapies, AOD9604 does not meaningfully elevate IGF1 levels (human data), which may reduce the risk of unwanted growthrelated side effects
(2023), provide notable evidence directly related to the use of single-use, disposable cystoscopes versus reusable cystoscopes
AOD-9604 plus growth hormone secretagogues Combining AOD-9604 with growth hormone secretagogues like CJC-1295/Ipamorelin creates a synergistic approach to body composition
